(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization

International Bureau





(43) International Publication Date 22 January 2004 (22.01.2004)

(10) International Publication Number WO 2004/007543 A1

(51) International Patent Classification7: C07K 14/47, 14/475, 14/65, C07H 21/04, A61K 38/17, 38/18, 38/30, A61P 35/00

(21) International Application Number:

PCT/AU2003/000898

(22) International Filing Date:

11 July 2003 (11.07.2003)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

2002950188

12 July 2002 (12.07.2002) AU

(71) Applicant (for all designated States except US): THE UNIVERSITY OF ADELAIDE [AU/AU]; North Terrace, Adelaide, S.A. 5000 (AU).

(72) Inventor; and

(75) Inventor/Applicant (for US only): FORBES, Briony [AU/AU]; University of Adelaide, North Terrace, Adelaide, S.A. 5000 (AU).

(74) Agent: A.P.T. PATENT AND TRADE MARK ATTOR-NEYS; PO Box 222, Mitcham, S.A. 5062 (AU).

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

with international search report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: ALTERED INSULIN-LIKE GROWTH FACTOR BINDING PROTEINS

Linker domain C-domain N -domain hIGFBP-2 食 191 4117-170 hIGFBP-2

2004/007543 A1 (57) Abstract: Altered IGFBPs are able to bind IGF but the release is inhibited by resistance to protease cleavage and/or reduced binding to extracellular matrix (ECM). Alterations have been made in IGFBP-2 to the linker domain in particular and two amino acid motifs found to be important for ECM binding. IGF-1 mediated proliferation of cancer cells have been inhibited by the use of these altered IGFBPs.

